Works matching IS 25094254 AND DT 2024 AND VI 8 AND IP 1
Results: 12
Acknowledgement to Referees.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 1, p. 1, doi. 10.1007/s41669-023-00456-5
- Publication type:
- Article
The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 1, p. 5, doi. 10.1007/s41669-023-00455-6
- By:
- Publication type:
- Article
Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 1, p. 119, doi. 10.1007/s41669-023-00454-7
- By:
- Publication type:
- Article
Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH).
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 1, p. 133, doi. 10.1007/s41669-023-00453-8
- By:
- Publication type:
- Article
Preferences for Living Arrangements in Dementia: A Discrete Choice Experiment.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 1, p. 65, doi. 10.1007/s41669-023-00452-9
- By:
- Publication type:
- Article
Cost of Patients with Alzheimer's Disease in Spain According to Disease Severity.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 1, p. 103, doi. 10.1007/s41669-023-00451-w
- By:
- Publication type:
- Article
Developing a Natural History Model for Duchenne Muscular Dystrophy.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 1, p. 79, doi. 10.1007/s41669-023-00450-x
- By:
- Publication type:
- Article
United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 1, p. 49, doi. 10.1007/s41669-023-00448-5
- By:
- Publication type:
- Article
Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 1, p. 115, doi. 10.1007/s41669-023-00447-6
- By:
- Publication type:
- Article
Specialist Palliative Care and Health Care Costs at the End of Life.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 1, p. 31, doi. 10.1007/s41669-023-00446-7
- By:
- Publication type:
- Article
Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 1, p. 91, doi. 10.1007/s41669-023-00445-8
- By:
- Publication type:
- Article
Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE<sup>®</sup>) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 1, p. 19, doi. 10.1007/s41669-023-00432-z
- By:
- Publication type:
- Article